Abstract
The introduction of nivolumab and pembrolizumab has radically changed the treatment landscape in patients with Non-small Cell Lung Cancer (NSCLC). The study objective is to compare the first-year costs of care associated with NSCLC for the historical (2011-2015) and novel (2016-2017) treatment eras among Medicare beneficiaries. The historical and novel treatment era was defined as the pre and post-approval of nivolumab and pembrolizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
